ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Durham, NC, USA:

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Chapel Hill, North Carolina, United States and 9 other locations

This randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative...

Active, not recruiting
HER2 Negative
Triple Negative Breast Cancer
Other: Quality-of-Life Assessment
Drug: Carboplatin

Phase 2

Vanderbilt University Medical Center
Vanderbilt University Medical Center

Chapel Hill, North Carolina, United States and 5 other locations

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo a...

Active, not recruiting
Breast Cancer
TNBC - Triple-Negative Breast Cancer
Drug: Trilaciclib
Drug: Placebo

Phase 3

G1 Therapeutics

Durham, North Carolina, United States and 70 other locations

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).The Following drugs will be ...

Active, not recruiting
Inflammatory Breast Cancer (IBC)
Drug: Paclitaxel
Drug: Cyclophosphamide

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Durham, North Carolina, United States and 3 other locations

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Placebo
Drug: Atezolizumab

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Cary, North Carolina, United States and 216 other locations

avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage I...

Enrolling
Stage IIIA Breast Cancer
Recurrent Breast Carcinoma
Biological: Utomilumab
Biological: Anti-OX40 Antibody PF-04518600

Phase 2

Hope Rugo, MD

Durham, North Carolina, United States and 11 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Chapel Hill, North Carolina, United States of America and 144 other locations

study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-...

Not yet enrolling
Breast Cancer
Triple Negative Breast Cancer
Biological: iC9-CAR.B7-H3 T Cell Therapy
Drug: cyclophosphamide

Phase 1

UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, United States

(pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative ...

Enrolling
Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
Triple Negative Breast Cancer
Drug: Paclitaxel
Drug: Carboplatin

Phase 2

Laura M. Spring, MD

Durham, North Carolina, United States and 9 other locations

Locations recently updated

(HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative...

Enrolling
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Drug: ABBV-400

Phase 1

AbbVie
AbbVie

Durham, North Carolina, United States and 35 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems